New drug combo shows promise in tough pancreatic cancer trial
NCT ID NCT05052723
First seen Nov 19, 2025 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tested a combination of two drugs, cabozantinib and pembrolizumab, in 21 people with metastatic pancreatic cancer that had worsened after standard treatments. The goal was to see if the combination could slow cancer growth or shrink tumors. The study measured how long patients lived without the cancer getting worse and how many responded to the therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Kentucky Markey Cancer Center
Lexington, Kentucky, 40536, United States
Conditions
Explore the condition pages connected to this study.